 
						
								INTRODUCTION							
							
								Focus on two main therapeutics, Ophthalmology and Surgical arena of skin surface wounds, while selectively pursue therapeutics in Neurology, Oncology and Orthopaedics							
						
								Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialized biologics marketed in China since 1998.
Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun(適麗順®)(Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 14,100 hospitals and managed directly by its 46 regional sales offices in China.
Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
						Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun(適麗順®)(Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 14,100 hospitals and managed directly by its 46 regional sales offices in China.
Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
 
						
								MILESTONES							
						
										1990-2000									
									
									
													1990												
												
													R&D team established, started the research and development of rb-bFGF												
											
													1996												
												
													Established rb-bFGF API and preparation production plant												
											
													1998												
												
													1st rb-bFGF surgical product Beifuji launched in China												
											
													1999												
												
													1st rb-bFGF ophthalmic product Beifushu Eye Drops launched in China												
											
										2001-2010									
									
									
													2001												
												
													Listed on GEM of HKEx												
											
													2003												
												
													Own sales network in China established												
											
													2005												
												
													2nd generation rb-bFGF products:Beifuxin Gel and Beifushu Eye Gel launched in China												
											
													2006												
												
													Beifushu became a well-known Rx ophthalmic brand in China and entered the forefront of China's ophthalmic prescription drug sales												
											
													2010												
												
													Company’s sales and distribution network enlarged to approximately 1,300 hospitals, managed directly by its 23 regional sales offices in China												
											 
								
										2011-now									
									
									
													2011												
												
													Listed on Main Board of HKEx ,stock code: 1061.HK												
											
													2014												
												
													New production plant put into operation												
											
													2015												
												
													Initiated Enrichment Programme to leverage external innovation												
											
													2018												
												
													Three unit-dose eye drops obtained approval from NMPA for commercialisation												
											
													2019												
												
													First global clinical program (VISTA-1) initiated in U.S.												
											
													2019												
												
													3rd generation of rb-bFGF Eye Drops approved for commercialisation in China and entered National Major Scientific and Technological Special Project for“Significant New Drugs Development”												
											
													2020												
												
													The second production plant FUTURE ONE started construction												
											
													2020												
												
													First Overseas Research Centre: U.S Boston Centre opened												
											
													2021												
												
													Positive outcome of VISTA-2												
											
													2022												
												
													Cyclosporine eye drops enters phase 2 clinical trial in NMPA, China												
											
													2022												
												
													Completed 适丽顺® acquisition												
											
													2022												
												
													Secured Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech												
											
													2023												
												
													Obtained the exclusive agency rights for PELNAC™ (China) and Osteopore' s dental and oral maxillofacial products (Singapore)												
											
													2023												
												
													Launched high-end home phototherapy brands 佩特® (PAINT), 艾视优加® (EYESU+) dry eye care products and FarFlex® series of elastic bandages												
											
													2024												
												
													Became the exclusive distributor of  SCALGEN® (China)												
											
													2024												
												
													Unit-dose Diquafosol Sodium Eye Drops and Sodium Hyaluronate Eye Drops (0.3%) obtained approval for commercialisation in China												
											
													2025												
												
													Multi-dose diquafosol sodium eye drops obtained approval from NMPA for commercialisation												
											
													2025												
												
													BLA for Bevacizumab was accepted by NMPA												
											
						CONTACT US					
					
									Head Office
in Hong Kong
								in Hong Kong
Address
											Room 3206, West Tower, Shun Tak Centre, 168-200 Connaught Road, Hong Kong SAR, China
										Tel
											(852) 2587 7838
										Fax
											(852) 2587 7363
										Email
											
												essex@essexbio.com																																																											
										
									Headquarter
in Zhuhai
								in Zhuhai
Address
											No.88, Keji 6th Road, Hi-Tech Zone, Zhuhai, Guangdong, China
										Tel
											(86) 756 3911188
										Fax
											(86) 756 3911185
										 
				 
										 
										 
										 
										 粤公网安备 44049102496184号
粤公网安备 44049102496184号